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Abstract Human tracheal glands are considered as the principle 
secretory structures in the bronchotracheal tree. In earlier stud- 
ies, we successfully performed primary cultures of human tra- 
cheal gland (HTG) serous cells and noted that these cells were 
responsive to many secretagogues including purinergic agonists 
but not to the inflammatory mediator adenosine. In this study, we 
demonstrate that adenosine was capable of inducing stimulation 
of protein secretion by HTG serous cells which had previously 
been cultured in pro-inflammatory conditions (induced by lipopol- 
ysaccharide (LPS)). This stimulation was inhibited by 8-phen- 
yltheophylline but not by dipyridamole, which is indicative of a 
P1 purinoceptor. This inducible receptor is of the adenosine A2 
subtype [rank potency order: 5'-(N-ethyl)-carboxamidoadenosine 
(NECA) > adenosine > N6-(phenylisopropyl)-adenosine (PIA); 
and stimulation of adenylyl cyclase]. The adenosine-induced pro- 
tein secretion was concentration-dependent, however, increased 
intracellular cyclic adenosine monophosphate (cAMP) was not 
dependent on the concentration of adenosine. The adenosine- 
induced secretion and the ATP-induced secretion were shown to 
be additive. This study concludes that there is evidence of a 
LPS-inducible adenosine A2 receptor in human tracheal gland 
serous cells. 
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I. Introduction 
Human tracheal glands are considered as the major secretory 
cells in the bronchotracheal tree [1]. They are composed of 
mucous cells, producing mucins, and serous cells which are 
responsible for the secretion of antibacterial nd antiproteolytic 
proteins [2]. We successfully performed primary cultures of 
human tracheal gland cells [3,4]. In culture, these cells were 
shown to be of the serous type [3] and to have retained most 
of their in vivo epithelial and secretory characteristics, such as 
secretion of the three specific serous secretory markers: bron- 
chial inhibitor (Brl), lysozyme and lactoferrin and their ability 
to respond to adrenergic and cholinergic agonists. Conse- 
quently, human tracheal gland serous (HTGS) cells can be 
considered as a valuable tool in the study of the regulation of 
the human bronchial secretion at a cellular and a molecular 
level. 
Adenosine is a potent secretagogue which has been shown 
to act via different mechanisms. It is recognized by purinergic 
receptors called P1 which are antagonized by methylxanthines 
[5]. A further classification of the P1 receptor into A1, A2 and 
A3 was achieved by the use of 5' and N%substituted analogues 
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of adenosine and also by positive or negative coupling of the 
receptor with adenylyl cyclase [6]. The A2 receptor is linked to 
the activation of adenylyl cyclase and is activated by adenosine 
analogues with the potency order: NECA ([N-ethyl]-carbox- 
yamido-adenosine) > adenosine > PIA (N6-[phenylisopropyl] - 
adenosine). The A1 receptor is characterized by an inversed 
potency order and its coupling to the inhibition of adenylyl 
cyclase. Recently, another adenosine receptor, the A3 ade- 
nosine receptor, was characterized and was also linked to the 
inhibition of adenylyl cyclase [7]. 
Adenosine metabolism in the lung has been examined mainly 
in the context of asthma [8], where it was shown to induce 
bronchoconstriction. In contrast, adenosine isvirtually inactive 
in non-asthmatics. Moreover, it has been shown that the lung 
itself is able to release adenosine in sufficient concentrations to 
significantly induce anaphylactic broncho-constrictions [9]. 
There is little data however, concerning the possible action of 
adenosine in other pulmonary pathological situations or its 
effects on airway macromolecule s cretion. 
Cystic fibrosis (CF) is a genetic disease characterized by 
mucus hypersecretion, persistent bacterial infection and inflam- 
mation of the airways. The defect lies in mutations of a mem- 
brane protein called CFTR (Cystic Fibrosis Transmembrane 
conductance Regulator) [10], possessing a cAMP-dependent 
chloride channel activity [11]. A chloride channel distinct from 
CFTR, but which is not defective in cystic fibrosis can be 
activated by an incrase in intracellular calcium [12]. ATP is a 
potent secretagogue which binds to the nucleotide receptor P2 
resulting in intracellular calcium mobilization through phos- 
pholipase C [12]. ATP has been consequently proposed for use 
as a therapeutic agent for cystic fibrosis in order to bypass the 
defective function of CFTR, and to restore chloride secretion 
in CF patients [13]. 
In a previous tudy, we showed that ATP is able to stimulate 
macromolecule s cretion by HTGS cells through the mobiliza- 
tion ofintracellular calcium [14]. Since ATP is given to patients 
with inflamed airways and since ATP is easily hydrolyzable into 
its metabolite adenosine, the aim of our present study was to 
determine whether or not adenosine may be active on cultured 
HTGS cells during a pro-inflammatory situation. This latter 
state was induced by the lipopolysaccharide (LPS) from Pseu- 
domonas aeruginosa which is the major pathogen in CF. We 
illustrate hereby, that LPS induces the appearance of an ade- 
nosine A2 receptor generating a stimulation of secretion by 
HTGS cells. 
2. Materials and methods 
2.1. Chemica& and solutions 
Adenosine, adenosine-5'-monophosphate (AMP), adenosine-5'-di- 
phosphate (ADP), adenosine-5'-triphosphate (ATP), adenosine-5'- 
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thiotriphosphate (ATP?'S), dipyridamole, 8-phenyl-theophylline, 5'-(N- 
ethylcarboxamido)-adenosine (NECA), N6-(2-pfienylisopropyl)-ade - 
nosine (PIA), epinephrine, serotype 10 Pseudomonas aeruginosa 
lipopolysaccharide (LPS) and Dulbecco's modified Eagle's/Ham's F 12 
mixture (DMEM/FI2)  were obtained from Sigma (St. Louis, MO, 
USA). UItroser G is from Biosepra (Villeneuve la Garenne, France). 
All other chemicals were of cell culture grade. Stock solutions of each 
secretagogue or agent were prepared as follows: adenosine, AMR 
ADP, ATP and ATPTS were dissolved in the DMEM/F12 mixture at 
10 2 M and then the pH was adjusted to 7.0; dipyridamole (0.1 M) was 
dissolved in 95% ethanol; 8-phenyl-theophylline (0.2 M) in 65% ethanol 
and 0.3 M NaOH; NECA (0.15 M) in dimethylsulfoxide/ethanol 
[50%:50%; v/v); PIA (0.15 M) in dimethylsulfoxide and LPS 
(at 10 mg/ml) in DMEM/F12. All stock solutions were aliquoted and 
stored at -20°C until required. 
2.2. Cell cultm'c 
HTGS cells were obtained from the tracheal mucosa of young 
healthy adults who had died from cerebral trauma (three males aged 
17, 27 and 39 years). No anatomo-pathological anomalies of the tra- 
cheal mucosae were observed. The cells were isolated by enzymatic 
digestion and grown in a DMEM/F I2  mixture supplemented with 1% 
Ultroser G, 0.22 g/1 sodium pyruvate and 6 g/l glucose as previously 
described [3]. Epinephrine (2.5 yM from a 2.5 mM stock solution made 
in HCI N/1000 and stored at -80°C) was routinely added to the cell 
culture medium in order to provide optimal growth and differentiation 
[4]. The cells were passaged using 0.025% trypsin (Gibco) and 0.02% 
EDTA and used at the 3rd passage, 8 days after confluency had been 
reached because of an extended ifferentiated state at that moment 
[3,4]. Type 1 collagen coated. Falcon disposable tissue culture flasks 
were used. 
2.3. Bronchial inhibitor secretion 
Confluent cultures of HTGS cells grown on 24-well plates were 
rinsed 4 times for 1 h with serum free culture medium and then exposed 
for 30 minutes to nucleosides or agents. 40/11 of the culture medium 
was harvested and bronchial inhibitor (Brl) was directly measured by 
an immunoenzymatic echnique with a sensitivity of 2 ng/ml and a 
reproducibility -> 97% [15]. The polyclonal antibodies used were ex- 
tremely specific and were able to recognize the molecule even corn- 
plexed to mucins or to proteases. Thus, this method allowed accurate 
detection of the Brl in the culture medium. In order to determine the 
effects of LPS on the ability of the cells to respond to secretagogues, 
LPS was added to the cells 24 h before the pharmacological ssays. We 
used the concentration of 50 ~g/ml LPS because we have shown in a 
previous tudy that 5(i) k'/ml LPS gave a maximal increase in Brl secre- 
tion (unpublished ata). The BrI secretory rate (Brl S.R.) was defined 
as the ratio of the BrI secreted in the assays to that secreted in control 
experiments. These were plate wells in which only vehicle solutions were 
added at the same times as the wells where the drugs were added. Thc 
vehicle additions were shown to be ineffective on Brl secretion by 
HTGS cells. In each experiment the mean Brl secretory rate was deter- 
mined from quadruplicate assays. 
2.4. Qvclic AMP measurements 
Cyclic AMP was measured in ethanol extracts of cells grown on 
24-well plates using a commercially available nzyme immunoassay kit 
(Amersham, Los Ulis, France) which allows the detection of cAMP in 
the range of 14~10520 pg/ml with high reproducibility (accu- 
racy -> 95%). According to the manufacturer's specifications, this kit 
does not react with other adenine nucleosides (adenosine. AMP, ADP 
or ATP). The results of cAMP determinations were expressed as pico- 
moles per million cells. Extractions were carried out either alter 6 rain 
contact with increasing concentrations of adenosine ( 10 v M to 1(1 4 M ). 
or at increasing times alter the addition of 10 a M of adenosine which 
was shown to be the concentration giving the maximal secretory re- 
sponse. 
2.5. Statistics 
Each experiment was repeated at least three times on three different 
cultures of HTGS cells. All results were expressed as means + standard 
deviation (S.D./. The significance between the effects of the concentra- 
tions of agents and the effects of the agonists was determined by anal- 
ysis of variance (ANOVA). The difference between the agents and the 
concentrations of agents was isolated by the Scheff6's multiple compar- 
ison test. Statistics were carried out using a Macintosh and the Software 
"StatView 512+" (BrainPower Inc., Calabasas, Californiat. The signifi- 
cance of potentiating interactions was determined by comparing the 
mean difference between the measured values for Brl secretion with two 
agents, and the calculated additive value of the two agents acting alone. 
Statistical signilicance: *P < 0.05, **P < 0.01, ***P < 0.001. 
3. Results 
3. l. Evidence o /an  LPS-inducible adenosine receptor 
We examined  the possible act ion o f  LPS incubat ion  on the 
abil ity o f  the cells to respond to adenos ine  nucleosides.  In the 
absence o f  LPS, HTGS cells responded to ATP  and  ADP by 
a s t imulat ion  of  BrI secret ion as previous ly  descr ibed [14]. Fig. 
IA  shows  that the s t imu lat ions  o f  secretion were: + 70 _+ 11% 
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Fig. 1. Effects of adenosine nucleosides on human tracheal gland (HTGS) cell secretion. Third passage human tracheal gland cells were cultured as 
previously described in the text. Eight days after reaching confluency, cells were washed and exposed for 30 rain to 10 4 M of each agonist. The Brl 
secretory rate (Brl S.R.: ratio of BrI secreted by the assay to BrI secreted by control) was calculated and compared to control ('C'I which has a 
value = 1. Each point represents mean _+ S.D. for quadruplicates from three different experiments (n = 4). Statistical significances between the 
response to agents and the control in this and the following figures are indicated by *P < 0.05, **P < 0.01 and ***P < 0.001. (A) The magnitude 
of the Br[ secretion by HTGS cells indicates the presence of the P2-purinoceptor and the absence of the Pl-purinoceptor. (B) When cells were 
previously incubated uring 24 h with LPS, they remained responsive to ATP and ADP but acquired the ability to respond to AMP and adenosine, 
which is indicative of the presence of a P1 receptor. Data from representative experiments. 
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Fig. 2. Effects of 8-phenyltheophylline and dipyridamole on the ade- 
nosine induced secretion by HTGS cells. Third passage cells were 
grown and left for 7 days postconfluency. LPS was then added to a final 
concentration of 50 pg/ml and left with the cells for 24 hours. HTGS 
cells were then washed and exposed for 30 min with both agents in the 
presence or absence of 10 -4 M of adenosine. All agents were added to 
the cells simultaneously. The BrI secretory rate (S.R.) and statistical 
significances as for Fig. 1. Values are given as mean + S.D. of three 
expeirments (n= 4). Where no agent was added only the vehicle was 
added to the cells. Note that 8-phenyltheophylline (10/JM) antagonized 
the adenosine induced stimulation of BrI secretion whereas dipyrida- 
mole (10 pM) caused no effect. 
(P < 0.001) and + 21 + 10% (P < 0.05) for both agents, respec- 
tively. No stimulation was observed with AMP and adenosine. 
Following incubation of the cells for a period of 24 h with 50 
pg/ml of LPS, we observed that the stimulation of BrI secretion 
induced by ATP and ADP remained unchanged. In addition, 
AMP and adenosine licited a significant stimulation of the 
secretion of BrI (Fig. 1B). The magnitudes of secretion were: 
+ 18 + 14% (P < 0.05) and + 58 + 15% (P < 0.01) for AMP 
and adenosine, respectively. This increase in secretion induced 
by adenosine was antagonized by the Pl-purinoceptor selective 
antagonist 8-phenyltheophylline (10 pM) (Fig. 2). This concen- 
tration of 8-phenyltheophylline was proved to be ineffective per 
se on BrI secretion when added in the absence of adenosine. 
Furthermore, the response of the cells to adenosine was unaf- 
fected by the adenosine uptake inhibitor dipyridamole [16,17]. 
3.2• Characterization of  the LPS-inducible adenosine receptor 
In order to determine which type of adenosine subclass is 
expressed after HTGS cells have been cultured with LPS, the 
effects of adenosine analogues on BrI secretion were examined 
on LPS-pretreated HTGS cells. The effect of adenosine was 
reproduced by its analogues with a rank order of potency: 
NECA > adenosine > PIA, suggesting the involvement of an 
adenosine A2 receptor (Fig. 3). A 10 4 M concentration of each 
analogue gave maximal stimulation of secretion with the fol- 
lowing respective values: + 100 + 15% (P < 0.001), + 63 + 8% 
(P < 0.01) and + 51 + 6% (P < 0.02). The effective concentra- 
tions producing 50% of the maximal responses (ECs0) were 
1.8 _+ 0.1 pM,  2.9 _+ 0.3 /.tM and 7.2 + 0.6 /zM, respectively. 
None of these analogues were shown to be effective if cells had 
not initially been incubated for 24 h with LPS. 8-Phenyltheo- 
phylline completely reversed the increase in secretion induced 
by each of the adenosine analogues in the presence of  LPS (data 
not shown). 
Since cAMP is a second messenger known to be induced by 
a number of agonists in HTGS cells, we examined the ability 
of adenosine to induce changes in cAMP levels. Moreover, the 
activation of the adenosine A2 receptor has been described as 
being linked to a generation of intracellular cyclic AMP. As 
shown in Fig. 4A stimulation of LPS-pretreated HTGS cells 
with maximal doses of adenosine led to rapid increases in intra- 
cellular cAME We noted, however, a discrepancy between the 
concentration-dependent effects of adenosine on BrI secretion 
and cAMP generation (Fig. 4B). All the concentrations of ade- 
nosine tested gave maximal production of cAME Lower con- 
centrations produced only minimal stimulation of secretion but 
produced submaximal increases in cAME 
3.3. Additive actions of  ATP  and adenosine 
It is known that secretagogues, the effects of which are medi- 
ated by cAME can act in addition to other secretagogues acting 
through calcium mobilization [18]. We therefore xamined the 
effect of adenosine on BrI secretion when added with ATP 
using HTGS cells which had been pretreated for 24 h with LPS. 
The combination of adenosine and ATP showed additive ef- 
fects on BrI secretion. The responses were similar to that pre- 
dicted by summation of the effects of each agent added inde- 
pendently (Fig. 5). The responses to ATP, adenosine and ATP 
plus adenosine were: 67 + 10% (P < 0.01), 56 + 8% (P < 0.01) 
and 125 + 3% (P < 0.001), respectively. ATP/S,  a non-hydroly- 
sable analogue of ATP produced similar responses to those 
elicited by ATP when added either alone (62 _+ 8%, P < 0.01) 
or in a combination with adenosine (118 + 6%, P < 0.001). 
4. Discussion 
The aim of the present study was to determine the possible 
effects of a pro-inflammatory environment on the ability of 
human tracheal gland serous cells to respond to adenosine, 
which is known to be an inflammatory mediator and also a 
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Fig. 3. Dose dependency of the effects of adenosine and its analogues 
on stimulation of Brl secretion by HTGS cells. Third passage HTGS 
cells were grown and left for 7 days postconfluency. LPS was then 
added to a final concentration of 50/.tg/ml and left for 24 h with the 
cells. HTGS cells were then washed and exposed for 30 min to increas- 
ing concentrations of NECA (o), adenosine (o) or PIA (11). Each point 
represents means + S.D. for four experiments (n -- 4). 
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Fig. 4. Effects of adenosine on the generation of cyclic AMP by HTGS 
cells. Eight day confluent hird passage HTGS cells were washed and 
exposed to adenosine. Cyclic AMP was then extracted and measured 
at increasing times or concentrations of adenosine as described in the 
text. Each point represents means ± S.D. for duplicates t¥om three 
different experiments. Statistical significances as for Fig. 1, N.S. = not 
significant. (A) Adenosine (at 10 _4 M) provokes a rapid generation of 
cyclic AMP within the HTGS cells. Basal levels of cyclic AMP in 
unstimulated cells were 4.0 ± 0.4 picomol/106 cells. (B) Dose depend- 
ency of the effects of adenosine on the cAMP accumulation i HTGS 
cells. Cyclic AMP measurements were carried out 6 rain after adenosine 
addition to HTGS cells. 
metabolite of the therapeutic agent ATE We show here that 
HTGS cells which do not respond to adenosine are however 
responsive to this nucleoside when pro-inflammatory condi- 
tions are induced by LPS. In this case, adenosine led to a 
stimulation of secretion comparable to that induced on control 
cells by other well known secretagogues such as carbachol, 
isoproterenol or ATP [3,4,14]. It is unlikely that the observed 
effects were artefactual since 8-phenyltheophylline, an antago- 
nist of the PI adenosine receptor, totally inhibited the stimula- 
tion induced by adenosine. Furthermore, dipyridamole did not 
act on the adenosine-induced stimulation of secretion indicat- 
ing that the observed effects were not as a result of a possible 
adenosine uptake by the cells. 
There are some disparities in the literature regarding the 
presence of adenosine receptors on airways cells. Whilst exam- 
ining different airway epithelial cells, some authors describe the 
presence of an active adenosine A2 receptor [19,20], but others 
detected little or no action of adenosine [12,21]. In contrast o 
the above data, we found the presence of this receptor in HTGS 
cells only when submitted to pro-inflammatory conditions. Our 
observations lead us to the conclusion that HTGS cells may 
have the ability to respond differently to physiological agents 
depending on the pathological context. It is worth noting that 
Ali et al. described an adenosine A1 receptor as being inducible 
in the asthmatic airways [22]. 
The action of adenosine on ionic transport and bronchocon- 
striction has previously been described, but it is our under- 
standing that this work represents the first demonstration of an 
effect of adenosine on macromolecule s cretion. The ability of 
HTGS cells to respond to adenosine by increasing protein se- 
cretion may provide a new insight into the role of adenosine 
which is tbund in high concentrations during inflammation, 
HTGS cells being responsive to this inflammatory mediator 
during an "infection-like situation'. Indeed, the emergence of 
this ability of HTGS cells to be stimulated by adenosine in 
response to bacterial LPS may also underlie some physiological 
implications. It seems justifiable to hypothesize that cells spe- 
cialized in the defense of the bronchotracheal tree may reorien- 
tare the aptitude of their antibacterial/antiproteolytic system to 
be stimulated when respiratory infection occurs. However, if 
adenosine also provokes mucus secretion by mucus secretory 
cells (gland mucous cells or goblet cells) when LPS is present, 
then this may not be so beneficial in bronchial hypersecretory 
diseases uch as cystic fibrosis or acute exacerbations of asthma 
or COPD associated with respiratory infection. An analysis of 
adenosine-induced mucin secretion under a pro-inflammatory 
situation would therefore be of considerable interest. 
Both the potency order of adenosine analogues inducing 
secretion and the increase in cAMP generation provoked by 
adenosine are characteristic of those generally observed lk)r 
adenosine A2 receptor agonists. They also differed completely 
from the characteristics o fA  1 and A3 adenosine receptors [6,7]. 
Adenosine and its secretagogues provoked protein secretion 
which was similar to the induced chloride secretion by the same 
agents on other epithelial cells [20]. Adenosine-induced chloride 
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Fig. 5. Effects of ATP, adenosine or the combination or ATP plus 
adenosine on Br| secretion by HTGS cells. Third passage cells were 
grown and left for 7 days postconfluency. LPS was then added to a final 
concentration or 50/lg/ml and left ror 24 h with the cells. HTGS cells 
were then washed and exposed for 30 rain with ATP, adenosine or 
ATP + adenosine (all at 10 4 M). Brl secretory rate (SR.) and the 
statistical significance as for Fig. 1. Means ± S.D. are shown (n = 4). 
Responses to the combined agents were identical to those calculated by 
summation of the actions of each agent independently added. 
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secretion is mediated by an A2 adenosine receptor in several 
epithelia nd in the T84 cell line [20]. 
The effects of the combination of adenosine and ATP were 
additive which leads us to the conclusion that both agents may 
act through different intracellular mechanisms. This may be a 
relevant observation since ATP is a component easily hydroly- 
sable in adenosine. As a consequence, it is possible that the 
therapeutic agent ATP may also act through its metabolite 
adenosine resulting in unexpected effects when the airways are 
inflamed. It would be interesting, therefore, to investigate the 
actions of adenosine in airway cells provided by CF patients. 
This study demonstrates that adenosine stimulated protein 
secretion by a mechanism linked to an accumulation of cyclic 
AMP. However, adenosine continued to stimulate cyclic AMP 
production in concentrations which were not sufficient o pro- 
voke secretion. The reasons for this discrepancy are not clear. 
It can be suggested that more than one second messenger is
mobilized by the A2 receptor, and that the secretion is effective 
only when a optimal balance in the generation of these second 
messengers i  achieved. It can also be hypothesized that ade- 
nosine may have different physiological effects depending upon 
its concentration. In addition to protein secretion, HTGS cells 
have the capacity to participate in the ionic balance of mucus 
since they notably express the CFTR-chloride channel [23,24]. 
Our results are in contrast to those described in the T84 cell line 
in which an adenosine analogue was shown to induce a maxi- 
mal short circuit current at concentrations where no cyclic 
AMP was detectable [20]. In other studies, adenosine was 
shown to be unrelated to adenylyl cyclase involvement [25]. It 
has now been demonstrated that the adenosine receptor is a 
typical G protein-coupled receptor, which may be linked to 
second messengers other than adenylyl cyclase such as phos- 
pholipase A2 or C, or guanylyl cyclase [26]. Thus, it is difficult 
to relate adenylyl eyclase stimulation to its consequent biolog- 
ical response. However, in our case, both adenylyl cyclase stim- 
ulation and the potency order of analogues are clearly indica- 
tive of the A2 subtype nature of this adenosine receptor, and 
now a subsequent adenosine receptor classification into the 
A2A or the A2B subtype has to be performed preferably based 
on the order affinity of specific antagonists [5,27]. 
In conclusion, these results show that LPS from Pseudo- 
monas aeruginosa induces the expression of a P1 purinoceptor 
of the A2 adenosine subtype which leads to the stimulation of 
protein secretion. However, the mechanism of induction of this 
purinoceptor is not yet understood. 
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